Wang YH, Hagiwara S, Kazama H, Iizuka Y, Tanaka N, Tanaka J. Elotuzumab Enhances CD16-Independent NK Cell-Mediated Cytotoxicity against Myeloma Cells by Upregulating Several NK Cell-Enhancing Genes.
J Immunol Res. 2024 Feb 27; 2024:1429879.
2023年
■原著論文（英文）
Imaizumi Y, Iwanaga M, Nosaka K, Ishitsuka K, Ishizawa K, Ito S, Amano M, Ishida T, Uike N, Utsunomiya A, Ohshima K, Tanaka J, Tokura Y, Tobinai K, Watanabe T, Uchimaru K, Tsukasaki K. Validation of the iATL-PI prognostic index in therapeutic decision-making for patients with smoldering and chronic ATL: a multicenter study. Int J Hematol. 117(2):206-215, 2023.
Minakata D, Ishida T, Ando K, Suzuki R, Tanaka J, Hagiwara S, Ananthakrishnan R, Kuwayama S, Nishio M, Kanda Y, Suzuki K. Phase 2 results of idecabtagene vicleucel (ide?cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma. Int J Hematol 117(5):729-737, 2023.
Shibata S, Arai Y, Kondo T, Mizuno S, Harada K, Miyakoshi S, Uchida N, Maruyama Y, Eto T, Katsuoka Y, Matsue K, Nishiwaki K, Takada S, Doki N, Itoh M, Nagafuji K, Kawakita T, Tanaka J, Fukuda T, Atsuta Y, Yanada M. Advantages of a higher busulfan dose intensity in fludarabine-combined conditioning for patients with acute myeloid leukemia undergoing cord blood transplantation. Transplant Cell Ther 29(5):332.e1-332.e11.
Akahoshi Y, Nakasone H, Takenaka K, Yamasaki S, Nakamura M, Doki N, Tanaka M, Ozawa Y, Uchida N, Ara T, Nakamae H, Ota S, Onizuka M, Yano S, Tanaka J, Fukuda T, Kanda Y, Atsuta Y, Kako S, Yanada M, Arai Y. CMV reactivation after allogeneic HCT is associated with a reduced risk of relapse in acute lymphoblastic leukemia Blood Adv. 27;7(12):2699-2708, 2023.
Kawano Y, Kim K, Min CK, Koh Y, Ishizawa K, Kim SH, Ito S, Tanaka J, Uchiyama M, Ishida T, Kim JS, Moreau P, Martin T, Tada K, Risse ML, Suzuki K. Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: updated IKEMA subgroup analysis. Clinical Lymphoma Myeloma and Leukemia (in press)
Okada M, Shiseki M, Yoshinaga K, Mori N, MotojiT, Tanaka J. Intraclonal heterogeneity of t(11;14) in human malignant monoclonal gammopathies demonstrated by interphase FISH. Chromosome Science 25: 51-56, 2022.
Kinoshita R, Ishibashi M, Handa H, Sasaki M, Imai Y, Tanaka N, Ito S, Sunakawa-Kii M, Kaito Y, Asayama T, Komatsu N, Tanaka J, Odajima T, Sugimori H, Yamaguchi H, Inokuchi K, Tamura H. The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myeloma. Exp Hematol. 121:38-47.e2, 2023.
Sameshima Y, Okada M, Shiseki M, Mori N, Motoji T, Tanaka J. Establishment and Characterization of an Acute Lymphocytic Leukemia Cell Line Expressing CD13 and CD33 with a Complex Philadelphia Translocation. Intern Med 62: 697-701, 2023.
2022年
■原著論文（英文）
Ishiyama M, Shiseki M, Yoshinaga K, Ryuzaki M, Izuka Y,
Watanabe W, Tanaka N, Shinohara A, Hagiwara S, Tanaka J.
Very early increased platelet count within a week after
initiation of high-dose dexamethasone treatment is
associated with long-term response in newly diagnosed
immune thrombocytopenia patients. Acta Haematologica
2022;145(2):193-200, 2022.
Tsuji M, Kondo M, Onizawa F, Shishime O, Muramatsu S,
Matsuo Y, Sakai S, Tanaka J, Tagaya E. A case of lung
intravascular large B cell lymphoma developed with
respiratory failure rescued by corticosteroid prior to
definite diagnosis. Respir Med Case Rep. 37:101625, 2022.
Miyao K, Kuwatsuka Y, Murata M, Nagafuji K, Teshima T,
Takeuchi Y, Shiratori S, Najima Y, Uchida N, Tanaka M, Sawa
M, Ota S, Fukuda T, Ozawa Y, Kako S, Kawakita T, Ara T,
Tanaka J, Kanda Y, Atsuta Y, Kanda J, Terakura S; GVHD
Working Group and Donor/Source Working Group of the
Japanese Society for Transplantation and Cellular Therapy.
Antithymocyte Globulin Potentially Could Overcome an
Adverse Effect of Acute Graft-versus-Host Disease in
Matched-Related Peripheral Blood Stem Cell Transplantation.
Transplant Cell Ther 28(3):153.e1-153.e11.2022.
Kako S, Hayakawa F, Miyamura K, Tanaka J, Imai K, Kanda
J, Morishima S, Uchida N, Doki N, Ikegame K, Ozawa Y,
Takada S, Usui N, Ohtake S, Kiyoi H, Matsumura I, Miyazaki
Y, Ichinohe T, Fukuda T, Atsuta Y, Kanda Y. Decision
Analysis for Unrelated Bone Marrow Transplantation or
Immediate Cord Blood Transplantation for Patients with
Philadelphia Chromosome-Negative Acute Lymphoblastic
Leukemia in First Complete Remission. Transplant Cell Ther
28(3):161.e1-161.e10. 2022.
Miyata R, Miyabe C, Fukuya Y, Tanaka N, Tanaka J,
Ishiguro N. Skin lesions as the initial sign of systemic
relapse in a case of Waldenstr?m's macroglobulinemia. Int J
Dermatol (in press)
Mori N, Ohwashi M, Yoshinaga K, Ogasawara T,Marshall S,
Shiseki M, Sakura H, Tanaka J. Genetic alterations in
patients with chronic leucocytosis and persistent
thrombocytosis. J Genetics (in press)
Kaito S, Kurosawa S, Najima Y, Sakaida E, Shingai N,
Fukuda T, Tachibana T, Uchida N, Ozawa Y, Sawa M, Nakazawa
H, Ota S, Kato J, Nakamae H, Katayama Y, Eto T, Tanaka J,
Kanda Y, Atsuta Y, Arai Y, Kako S; Adult Acute
Lymphoblastic Leukemia Working Group of the Japan Society
for Hematopoietic Cell Transplantation. Allogeneic
hematopoietic stem cell transplantation for adult
Philadelphia chromosome-negative B-cell acute lymphoblastic
leukemia in second complete remission. Transplant Cell Ther
(in press)
Kim K, Min CK, Koh Y, Ishizawa K, Kim SH, Ito S, Tanaka
J, Uchiyama M, Kawano Y, Kim JS, Moreau P, Martin T, Dong
Y, Risse ML, Suzuki K. Isatuximab plus carfilzomib and
dexamethasone in East Asian patients with relapsed multiple
myeloma: IKEMA subgroup analysis. Int J Hematol. (in press)
Shimazu Y, Murata M, Kondo T, Minami Y, Tachibana T,
Doki N, Uchida N, Ozawa Y, Yano S, Fukuda T, Kato J, Ara T,
Eto T, Ishikawa J, Nakamae H, Tanaka J, Ichinohe T, Atsuta
Y, Nagamura-Inoue T; working group of the Japan Society for
Transplantation and Cellular Therapy. The new generation
tyrosine kinase inhibitor improves the survival of chronic
myeloid leukemia patients after allogeneic stem
cell transplantation. Hematol Oncol. (in press)
Nishiwaki S, Akahoshi Y, Morita M, Doki N, Uchida N,
Ozawa Y, Fukuda T, Tanaka M, Ikegame K, Ota S, Katayama Y,
Takahashi S, Kawakita T, Ara T, Onizuka M, Kimura T, Tanaka J,
Atsuta Y, Yasuyuki A. Improvements in allogeneic
hematopoietic cell transplantation outcomes for adults with
ALL over the past three decades. Blood Advances (in press)
Ishida H, Kato M, Kawahara Y, Ishimaru S, Najima Y,
Kako S, Sato M, Hiwatari M, Noguchi M, Kato K, Koh K, Okada
K, Iwasaki F, Kobayashi R, Igarashi S, Saito S, Takahashi
Y, Sato A, Tanaka J, Hashii Y, Atsuta Y, Sakaguchi H,
Imamura T. Prognostic factors of children and adolescents
with T-cell acute lymphoblastic leukemia after allogeneic
transplantation. Hematol Oncol. 2022 (in press)
Kanda Y, Doki N, Kojima M, Kako S, Inoue M, Uchida N, Onishi Y, Kamata R, Kotaki M, Kobayashi R, Tanaka J, Fukuda T, Fujii N, Miyamura K, Mori S, Mori Y, Morishima Y, Yabe H, Atsuta Y, Kodera Y. Effect of Cryopreservation in Unrelated Bone Marrow and Peripheral Blood Stem Cell Transplantation in the Era of the COVID-19 Pandemic: An Update from the Japan Marrow Donor Program. Transplant Cell Ther 28(10):677.e1-677.e6.2022.
Yanada M, Matsuda K,Ishii H, Fukuda T, Ozeki K, Ota S, Tashiro H, Uchida N, Kako S, Doki N, Kawakita T, Onishi Y, Takada S, Kondo Y, Tanaka J, Kanda Y, Atsuta Y, Yano S.
Allogeneic hematopoietic cell transplantation for patients with relapsed acute promyelocytic leukemia. Transplant Cell Ther Sep 27;S2666-6367(22)01659-1.2022.
Ishida T, Ito S, Tanaka J, Uchiyama M, Kawano Y, Moreau P, Martin T, Risse ML, Tada K, Suzuki K, Ishizawa K. Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomised, open label, phase 3 IKEMA study. Japanese Journal of Clinical Oncology (in press)
Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a Salvage and Bridging Regimen before Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma.
Togano T, Andoh S, Komuro M, Mitsui Y, Itoi S, Hirai R, Nakamura M, Tanimura A, Sekine R, Takeshita M, Miwa A, Hagiwara S.
Intern Med. 2022 Apr 23. doi: 10.2169/internalmedicine.9097-21. Online ahead of print.
PMID: 35466165
2021年
■総説論文（英文）
Tanaka J. Recent advances in chimeric antigen receptor NK cell therapy for overcoming intractable hematological malignancies. Hematological Oncology 39:11-19, 2021.
Tanaka J. Recent advances in cellular therapy for malignant lymphoma. Cytotherapy 23:662-671, 2021.
■原著論文（英文）
Nishiwaki S, Akahoshi Y, Mizuta S, Shinohara A, Hirabayashi S, Noguchi Y, Fukuda T, Uchida N, Tanaka M, Onizuka M,
Ozawa Y, Ota S, Shiratori S, Onishi Y, Kanda Y, Sawa M, Tanaka J, Atsuta Y, Kako S. Measurable residual disease impacts allogeneic hematopoietic cell transplantation in Ph+ALL
during both CR1 and CR2. Blood Advances 5(2):584-592, 2021.
Morishima S, Fukuda T, Doki D, Mori T, Onizuka M, Kawakita T, Kato C, Ozawa Y, Tanaka M, Kurokawa M, Kamimura T, Inoue M, Tanaka J, Ichinohe T, Atsuta Y, Morishima Y. Individual HLAs influence immunological events in allogeneic stem cell transplantation from HLA-identical sibling donors. Bone Marrow Transplant. 56(3):646-654, 2021.
Kanda Y, Inoue M, Uchida N, Onishi Y, Kamata R, Kotaki M, Kobayashi R, Tanaka J, Fukuda T, Fujii N, Miyamura K, Mori SI, Mori Y, Morishima Y, Yabe H, Kodera Y. Cryopreservation of unrelated hematopoietic stem cells from a blood and marrow donor bank during the COVID-19 pandemic. A nationwide survey by the Japan Marrow Donor Program. Transplant Cell Ther. 27(8):664.e1-664.e6.2021.
Akahoshi Y, Arai Y, Nishiwaki S, Mizuta S, Marumo A, Uchida N, Kanda1 Y, Sakai H, Takada S, Fukuda T, Fujisawa S, Ashida T, Tanaka J, Atsuta Y, Kako S. Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome positive acute lymphoblastic leukemia. Int J Hematol 2021 Jun;113(6):832-839.
Watanabe A, Shiseki M, Oishi M, Kobayashi M, Oshima S, Osanai S, Ryuzaki M, Izuka Y, Tanaka N, Ishiyama M, Shinohara A, Kazama H, Hagiwara S, Yoshinaga K, Tanaka J. Successful Rituximab Treatment in Thrombotic Thrombocytopenic Purpura Patients Complicated by Other Autoimmune Disorders: Two Case Reports.
Intern Med (in press)
Shiseki M, Ohwashi-Miyazaki M, Yoshinaga K,Mori N, Tanaka J.High PRAME expression is associated with poor survival and early disease progression in myelodysplastic syndromes with a low bone marrow blast percentage. Leukemia and Lymphoma (in press)
Shimomura Y, Hara M, Konuma T, Itonaga H, Doki N, Ozawa Y, Eto T, Uchida N, Aoki J, Kato J, Onishi Y, Takahashi S, Fukushima K, Nakamae H, Kawakita T, Tanaka J, Fukuda T, Atsuta Y, Ishikawa T, Ishiyama K. Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients. Bone Marrow Transplant (in press)
Yasui H, Kobayashi M, Sato K, Kondoh K, Ishida T, Kaito Y, Tamura H, Handa H, Tsukune Y, Sasaki M, Komatsu K, Tanaka N, Tanaka J, Kizaki M, Kawamata T, Makiyama J, Yokoyama K, Imoto S, Tojo A, Imai Y. Circulating cell-free DNA in the patient’s peripheral blood plasma is a sensitive biomarker for multiple myeloma relapse. International Journal of Clinical Oncology (in press)
Akahoshi Y, Arai Y, Nishiwaki S, Tachibana T, Shinohara A, Doki N, Uchida N, Tanaka M, Kanda Y, Shiratori S, Ozawa Y, Shono K, Katayama Y, Tanaka J, Fukuda T, Atsuta Y, Kako S. Newly proposed threshold and validation of white blood cell count at diagnosis for Philadelphia chromosome-positive acute lymphoblastic leukemia: Risk assessment of relapse in patients with negative minimal residual disease at transplantation—A Report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT. Bone Marrow Transplant (in press)
Kako S, Hayakawa F, Imai K, Tanaka J, Mizuta S, Nishiwaki S, Kanamori H, Doki N, Ozawa Y, Kondo T, Fukuda T, Ichinohe T, Ota S, Tanaka Y, Murayama T, Kurahashi S, Sakura T, Usui N, Ohtake S, Kiyoi H, Matsumura I, Miyazaki Y, Atsuta Y.
The optimal treatment for Philadelphia-negative ALL in first remission in the era of high-intensity chemotherapy. Int J Hematol (in press)
Ishiyama M, Shiseki M, Yoshinaga K, Ryuzaki M, Izuka Y, Watanabe W, Tanaka N, Shinohara A, Hagiwara S, Tanaka J. Very early increased platelet count within a week after initiation of high-dose dexamethasone treatment is associated with long-term response in newly diagnosed immune thrombocytopenia patients. Acta Haematologica (in press)
Yasui, H., M. Kobayashi, K. Sato, K. Kondoh, T. Ishida, Y. Kaito, H. Tamura, H. Handa, Y. Tsukune, M. Sasaki, N. Komatsu, N. Tanaka, J. Tanaka, M. Kizaki, T. Kawamata, J. Makiyama, K. Yokoyama, S. Imoto, A. Tojo and Y. Imai (2021).
"Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse." Int J Clin Oncol. 2021 Jul 14. Online ahead of print.
2020年
■総説論文（英文）
Junji Tanaka, Jeffrey S. Miller. Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies. Blood Reviews 44:100678, 2020.
■原著論文（英文）
Tanaka J, Tanaka N, Wang YH, Mistuhashi K, Ryuzaki M, Iizuka Y, Watanabe A, Ishiyama M, Shinohara A, Kazama H, Hagiwara S, Yoshinaga K, Kougen Y, Kobayashi H, Kanno H, Shiseki M. Phase I study of cellular therapy using ex vivo expanded NK cell from autologous peripheral blood mononuclear cells combined with rituximab-containing chemotherapy for relapsed CD20-positive malignant lymphoma patients. Haematologica 105: e190-e193, 2020.
Shinohara A, Oshima K, Fuji S, Umeda K, Kako S, Kurokawa M, Tsukada N, Kasai M, Kondo T, Hashii Y, Nakamae H, Ikegame K, Kosaka Y, Shimada A, Nawa Y, Makoto Y, Yoshiko A, Fukuda T, Tanaka J, Ogata M. Hematopoietic stem cell transplantation in solid organ recipients with emphasis on transplant complications: a nationwide retrospective survey on behalf of the JSHCT, transplant complications working group.
Biol Blood Marrow Transplant. 26(1):66-75, 2020.
Arima N, Kanda J, Yabe T, Morishima Y, Tanaka J, Kako S, SakaguchiH, Kato M, Ohashi K, Ozawa Y, Fukuda T, Ota S, Tachibana T, Onizuka M, Ichinohe T, Atsuta Y, Kanda Y. Increased Relapse Risk of Acute Lymphoid Leukemia in Homozygous HLA-C1 Patients after HLA-matched Allogeneic Transplantation: A Japanese National Registry Study. Biol Blood Marrow Transplant. 26: 431-437, 2020.
Kanda J, Kawase T, Tanaka H, Kojima H, Morishima Y, Uchida N, Nagafuji K, Matsuhashi Y, Ohta T, Onizuka M, Sakura T, Takahashi S, Miyakoshi1 S, Kobayashi H, Eto T, Tanaka J, Ichinohe T, Atsuta Y, Morishima S. On behalf of the HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation. Effects of haplotype matching on outcomes after adult single cord blood transplantation. Biol Blood Marrow Transplant. 26: 509-518, 2020.
Shiseki M, Ohwashi-Miyazaki M, Yoshinaga K,Mori N, Tanaka J. Reduced PLCG1 expression is associated with inferior survival for myelodysplastic syndromes. Cancer Medicine 9(2):460-468, 2020.
Ishibashi M, Takahashi R, Tsubota A, Sasaki M, Handa H, Imai Y, Tanaka N, Tsukune Y, Tanosaki S, Ito S, Asayama T, Sunakawa M, Kaito Y, Kuribayashi-Hamada Y, Kondo-Onodera A, Moriya K, Komatsu N, Tanaka J, Odajima T, Sugimori H, Inokuchi K, Tamura H. SLAMF3-mediated signaling via ERK pathway activation promotes aggressive myeloma behaviors in multiple myeloma. Molecular Cancer Research 18(4):632-643, 2020.
Akahoshi Y, Igarashi A, Fukuda T, Uchida N, Tanaka M, Ozawa Y, Kanda Y, Onizuka M, Ichinohe T, Tanaka J, Atsuta Y, Kako S.
Impact of graft-versus-host disease and graft-versus-leukemia effect based on minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemia. Br J Haematol 190(1):84-92, 2020.
Kaito S, Najima Y, Harada H, Fukuda T, Noguchi Y, Ikegame K, Tanaka M, Ozawa Y, Yoshida S, Sawa M, Ota S, Inoue Y,
Tanaka J, Ichinohe T, Atsuta Y, Kako S. Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia harboring t(1;19)(q23;p13.3); comparison with normal karyotype". Bone Marrow Transplant.(in press)
Morishima S, Fukuda T, Doki D, Mori T, Onizuka M, Kawakita T, Kato C, Ozawa Y, Tanaka M, Kurokawa M, Kamimura T, Inoue M, Tanaka J, Ichinohe T, Atsuta Y, Morishima Y. Individual HLAs influence immunological events in allogeneic stem cell transplantation from HLA-identical sibling donors. Bone Marrow Transplant.(in press)
Akahoshi Y, Nishiwaki S, Arai Y, Harada K, Najima Y, Kanda Y, Shono K, Ota S, Fukuda T, Uchida N, Shiratori S, Tanaka M, Tanaka J, Atsuta Y, Kako S. Reduced-intensity conditioning is a reasonable alternative for philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease. Bone Marrow Transplant (in press)
Kako S, Akahoshi Y, Nishiwaki S, Arai Y, Harada K, Najima Y, Kanda Y, Shono K, Ota S, Fukuda T, Uchida N, Shiratori S, Tanaka M, Tanaka J, Atsuta Y. Reduced-Intensity Conditioning is a Reasonable Alternative for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Among Elderly Patients who have Achieved Negative Minimal Residual Disease: A Report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT. Bone Marrow Transplant (in press)
Tanaka, N., Y. Imai, K. Yoshinaga, M. Shiseki and J. Tanaka (2020).
"Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities." Ann Hematol 99(11): 2577-2586.
2019年
■原著論文（英文）
Yamasaki S, Chihara D, Yoshida I, Kohda K, Sawa M, Ago H, Togitani K, Ohno Y, Tanaka J, Fukuda T, Atsuta Y, Suzumiya J, Suzuki R. Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory marginal zone lymphoma.
Annals of Hematology 98:1521–1523, 2019.
Yanada M, Masuko M, Mori J, Aoki J, Mizuno S, Fukuda T, Kakihana K, Ozawa Y, Ota S, Kanamori H, Mori T, Eto T, Shiratori S, Maeda T, Iwato K, Ichinohe T, Kanda Y, Tanaka J, Atsuta Y, Yano S. Patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: trends in survival during the past two decades. Bone Marrow Transplant. 54(4):578-586, 2019.
Yoshimitsu M, Utsunomiya A, Fuji S, Fujiwara H, Fukuda T, Ogawa H, Takatsuka Y, Ishitsuka K, Yokota A, Okumura H, Ishii K, Nishikawa A, Eto T, Yonezawa A, Miyashita K, Tsukada J, Tanaka J, Atsuta Y, Kato K. A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without post-transplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia-lymphoma. Bone Marrow Transplant. 54(8):1266-1274, 2019.
Fujimoto A, Hiramoto N, Yamasaki S, Inamoto Y, Uchida N, Maeda T, Mori T, Kanda Y, Kondo T, Tanaka J, Ichinohe T, Atsuta Y, Ogata M, Suzuki R. Risk Factors and Predictive Scoring System
for Post-Transplant Lymphoproliferative Disorder
after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 25(7):1441-1449, 2019.
Kato K, Mori T, Kim SW, Sawa M, Sakai T, Hashimoto H, Taguchi J, Oyake T, Kurahashi S, Imada K, Ohno H, Tanaka J, Ichinohe T, Atsuta Y, Suzuki R, Suzumiya J. Outcome of patients receiving consolidative autologous peripheral blood stem cell transplantation in the frontline treatment of intravascular large B-cell lymphoma: Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation" Bone Marrow Transplant. 54(9):1515-1517, 2019.
Hangai M, Urayama KY, Tanaka J, Kato K, Nishiwaki S, Koh K, Noguchi M, Kato K, Yoshida N, Sato M, Goto H, Yuza Y ,
Hashii Y, Atsuta Y, Mizuta S, Kato M. Allogeneic stem cell transplantation for acute lymphoblastic leukemia in adolescents and young adults. Biol Blood Marrow Transplant. 25(8):1597-1602, 2019.
Hagiwara S, Nagai H, Tanaka J, Okada S. The current state of human immunodeficiency virus-associated lymphoma in Japan: a nationwide retrospective study of the Japanese Society of Hematology Blood Disease Registry. Int J Hematol 110:244-249, 2019.
Shinohara S, Osanai S, Izuka Y, Ryuzaki M, Watanabe A, Tanaka N, Ishiyama M, Kazama H, Hagiwara S, Yoshinaga K, Shiseki M, Tanaka J. Herpes zoster after autologous hematopoietic stem cell transplantation without antiviral prophylaxis. Br J Haematol 186(6):e195-e197, 2019.
Nishiwaki S, Mizuta S, Ohashi K, Fukuda T, Uchida N, Tachibana T, Onizuka M, Ozawa Y, Onishi Y, Takahashi S, Eto T, Nakamae H, Tanaka J, Ichinohe T, Atsuta Y, Kako S. Different impact of BCR-ABL transcripts on allogeneic hematopoietic cell transplantation from different graft sources for Ph+ALL with minimal residual disease. Am J Hematol. Nov;94(11):E301-E305, 2019.
Yano S, Yokoyama H, Yanada M, Mori J, Aoki J, Ohashi K, Kanamori H, Ozawa Y, Sawa M, Nakamae H, Eto T, Ota S, Tanaka J, Ichinohe T, Atsuta Y, Takami A. Role of Alternative Donor Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate- or Poor-risk Acute Myeloid Leukemia in First Complete Remission. Bone Marrow Transplant. 54(12):2004-2012, 2019.
Shiseki M, Ohwashi-Miyazaki M, Yoshinaga K,Mori N, Tanaka J. Title Expression analysis of genes located within the common deleted region of del(20q) in patients with myelodysplastic syndromes. Leukemia Research 2019 Sep;84:106175.
Harada K, Tachibana T, Ohashi K, Ozawa Y, Sawa M, Kondo T, Ishikawa J, Onizuka M, Imada K, Fujisaki T, Tanaka J, Fukuda1 T, Atsuta Y, Kako S. The effect of melphalan dose and total body irradiation as reduced-intensity conditioning for acute lymphoblastic leukemia patients undergoing allogeneic stem cell transplantation. Leuk Lymphoma. 60(14):3521-3528, 2019.
2018年
■英文論文
1.Goto T, Tanaka T, Sawa M, Ueda Y, Ago H, Chiba S, Kanamori H, Nishikawa A, Nougawa M, Ohashi K, Okumura H, Tanimoto M, Fukuda T, Kawashima N, Kato T, Okada K, Nagafuji K, Okamoto SI, Atsuta Y, Hino M, Tanaka J, Miyamura K. Prospective observational study on the first 51 cases of peripheral blood stem cell transplantation from unrelated donors in Japan. Int J Hematol. 107(2):211-221, 2018.
Arai Y, Kondo T, Shigematsu A, Tanaka J, Ohashi K, Fukuda T, Hidaka M, Kobayashi N, Iwato K, Sakura T, Onizuka M, Ozawa Y, Eto T, Kurokawa M, Kahata K, Uchida N, Atsuta Y, Mizuta S, Kako S. Improved prognosis with additional medium-dose VP16 to CY/TBI in allogeneic transplantation for high risk ALL in Adults. American J Hematol 93(1):47-57, 2018.
Arima N, Kanda J, Tanaka J, Yabe T, Morishima Y, Kim SW, Najima Y, Ozawa Y, Eto T, Kanamori H, Mori T, Kobayashi N, Kondo T, Nakamae H, Uchida N, Inoue M, Fukuda T, Ichinohe T, Atsuta Y, Kanda Y. Homozygous HLA-C1 is associated with reduced risk of relapse after HLA-matched transplantation in patients with myeloid leukemia. Biol Blood Marrow Transplant. 24: 717–725, 2018.
Wang YH, Imai Y, Shiseki M, Tanaka J, Motoji T.Knockdown of the Wnt receptor Frizzled-1 (FZD1) reduces MDR1/P-glycoprotein expression in multidrug resistant leukemic cells and inhibits leukemic cell proliferation. Leuk Res. 67: 99-108, 2018.
Akahoshi Y, Mizuta S, Shimizu H, Uchida N, Fukuda T, Kanamori H, Onizuka M, Ozawa Y, Ohashi K, Ohta S, Eto T, Tanaka J, Atsuta Y, Kako S. Additional cytogenetic abnormalities with Philadelphia chromosome-positive acute lymphoblastic leukemia on allogeneic stem cell transplantation in the tyrosine kinase inhibitor era. Biol Blood Marrow Transplant. 24(10):2009-2016, 2018.
Ishibashi M, Soeda S, Sasaki M, Handa H, Imai Y, Tanaka N, Tanosaki S, Ito S, Odajima T, Sugimori H, Asayama T, Sunakawa M, Kaito Y, Kinoshita R, Kuribayashi Y, Onodera A, Moriya K, Tanaka J, Tsukune Y, Komatsu N, Inokuchi K, Tamura H. Clinical impact of serum soluble SLAMF7 in multiple myeloma. Oncotarget 78: 34784-34793, 2018.
Yanada M, Masuko M, Mori J, Aoki J, Mizuno S, Fukuda T, Kakihana K, Ozawa Y, Ota S, Kanamori H, Mori T, Eto T, Shiratori S, Maeda T, Iwato K, Ichinohe T, Kanda Y, Tanaka J, Atsuta Y, Yano S. Patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: trends in survival during the past two decades. BMT (in press) 2018 Aug 14. doi: 10.1038/s41409-018-0301-7. [Epub ahead of print]
Yoshimitsu M, Utsunomiya A, Fuji S, Fujiwara H, Fukuda T, Ogawa H, Takatsuka Y, Ishitsuka K, Yokota A, Okumura H, Ishii K, Nishikawa A, Eto T, Yonezawa A, Miyashita K, Tsukada J, Tanaka J, Atsuta Y, Kato K. A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without post-transplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia-lymphoma. BMT (in press)
Fujimoto A, Hiramoto N, Yamasaki S, Inamoto Y, Uchida N, Maeda T, Mori T, Kanda Y, Kondo T, Tanaka J, Ichinohe T, Atsuta Y, Ogata M, Suzuki R. Risk Factors and Predictive Scoring System for Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation. BBMT (in press)
Kato K, Mori T, Kim SW, Sawa M, Sakai T, Hashimoto H, Taguchi J, Oyake T, Kurahashi S, Imada K, Ohno H, Tanaka J, Ichinohe T, Atsuta Y, Suzuki R, Suzumiya J. Outcome of patients receiving consolidative autologous peripheral blood stem cell transplantation in the frontline treatment of intravascular large B-cell lymphoma: Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation" BMT (in press)
Hangai M, Urayama KY, Tanaka J, Kato K, Nishiwaki S, Koh K, Noguchi M, Kato K, Yoshida N, Sato M, Goto H, Yuza Y,Hashii Y, Atsuta Y, Mizuta S, Kato M. Allogeneic stem cell transplantation for acute lymphoblastic leukemia in adolescents and young adults. BBMT (in press)
Yano S, Yokoyama H, Yanada M, Mori J, Aoki J, Ohashi K, Kanamori H, Ozawa Y, Sawa M, Nakamae H, Eto T, Ota S, Tanaka J, Ichinohe T, Atsuta Y, Takami A. Role of Alternative Donor Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate- or Poor-risk Acute Myeloid Leukemia in First Complete Remission. BMT (in press)
Tanimura A, Hirai R, Nakamura M, Takeshita M, Hagiwara S, Miwa A. The Prognostic Impact of Dose-attenuated R-CHOP Therapy for Elderly Patients with Diffuse Large B-cell Lymphoma. Intern Med. 2018 Dec 15;57(24):3521-3528. Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone. Int J Hematol. 2018 May;107(5):559-567.
Yoshinaga N, Kanda J, Aisa Y, Hagiwara S, Mori T, Fukuda T, Ishida Y, Hashimoto H, Iwato K, Kanda Y, Kurokawa M, Nakazawa H, Ota S, Uchida N, Ichinohe T, Atsuta Y, Takaori-Kondo A. Impact of HIV Infection on Transplant Outcomes after Autologous Peripheral Blood Stem Cell Transplantation: A Retrospective Study of Japanese Registry Data.Biol Blood Marrow Transplant. 2018 Aug;24(8):1596-1601.
Yotsumoto M, Ito Y, Hagiwara S, Terui Y, Nagai H, Ota Y, Ajisawa A, Uehira T, Tanuma J, Ohyashiki K, Okada S. HIV positivity may not have a negative impact on survival in Epstein-Barr virus-positive Hodgkin lymphoma: A Japanese nationwide retrospective survey. Oncol Lett. 2018 Sep;16(3):3923-3928.
Kasamatsu T, Ozaki S, Saitoh T, Konishi J, Sunami K, Itagaki M, Asaoku H, Cho T, Handa H, Hagiwara S, Wakayama T, Negoro A, Takezako N, Harada N, Kuroda Y, Nakaseko C, Miyake T, Inoue N, Hata H, Shimazaki C, Ohno T, Kuroda J, Murayama T, Kobayashi T, Abe M, Ishida T, Nagura E, Shimizu K. Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma. Hematol Oncol. 2018 Dec;36(5):792-800.
■和文論文
田中淳司：血液腫瘍と腎障害
腎と透析 ８４巻４号：495-497, 2018.
2017年
■英文論文
Wang YH, Imai Y, Shiseki M, Tanaka J, Motoji T. Knockdown of the Wnt receptor Frizzled-1 (FZD1) reduces MDR1/P-glycoprotein expression in multidrug resistant leukemic cells and inhibits leukemic cell proliferation. Leuk Res. 2018 Apr; 67:99-108
Takenaka K, Shimoda K, Uchida N, Shimomura T, Nagafuji N, Kondo T, Shibayama H, Mori T, Usuki K, Azuma T, Tsutsumi Y, Tanaka J, Dairaku H, Matsuo T, Ozawa K, Kurokawa M, Arai S, Akashi K. Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan. Int J Hematol 105:59-69, 2017.
Arai Y, Kondo T, Shigematsu A, Tanaka J, OhasiK, Fukuda T, Kawakita T, Mori T, Hoshino T, Onizuka M, Ozawa Y, Yoshida S, Ueda Y, Mizuno I, Atsuta Y, Mizuta S. Increased non-relapse mortality due to high-dose cytarabine plus CY/TBI in BMT/PBSCT for acute lymphoblastic leukemia in adults. Br J Haematol 178(1):106-111, 2017.
Shigematsu A, Kako S, Mitsuhashi K, Iwato K, Uchida N, Kanda Y, Fukuda T, Sawa M, Senoo Y, Ogawa H, Miyamura K, Takada S, Nagamura-Inoue T, Morishima Y, Ichinohe T, Atsuta Y, Mizuta S, Tanaka J. Allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia who had central nervous system involvement: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation. Int J Hematol 105(6):805-811, 2017.
Mori N, Ohwashi-Miyazaki M, Yoshinaga K, Okada M, Shiseki M, Motoji T, Tanaka J. Tumor suppressor gene methylation on the short arm of chromosome 1 in chronic myelogenous leukemia. Eur J Haematol 98(5):467-477, 2017.
Mizutani M, Takami A, Hara M, Mizuno S, Yanada M, Chou T, Uchiyama H, Ohashi K, Miyamoto T, Ozawa Y, Imataki O, Kobayashi N, Uchida N, Kanamori H, Kamimura T, Eto T, Onizuka M, Tanaka J, Atsuta Y, Yano S. Comparison of Autologous and Unrelated Transplants for Cytogenetically Normal Acute Myelogenous Leukemia. Biol Blood Marrow Transplant. 23(9):1447-1454, 2017.
Tomizawa D, Tanaka S, Kondo T, Hashii Y, Arai Y, Kudo K, Taga T, Fukuda T, Goto H, Inagaki J, Koh K, Ohashi K, Ozawa Y, Inoue M, Kato K, Tanaka J, Atsuta Y, Adachi S, Ishida H. Allogeneic hematopoietic stem cell transplantation for adolescentsand young adults with acute myeloid leukemia. Biol Blood Marrow Transplant. 23(9):1515-1522, 2017.
Mori J, Yanada M, Uchida N, Fukuda T, Sakura T, Hidaka M, Watakabe-Inamoto K, Kanamori H, Ogawa H, Ichinohe T, Tanaka J, Atsuta Y, Yano S. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Abnormalities of the Short Arm of Chromosome 17. Biol Blood Marrow Transplant. 23(8):1398-1404, 2017.
Shiseki1 M, Yoshida C, Takezako N, Ohwada A, Kumaga T, Nishiwaki K, Horikoshi A, Fukuda T, Takano H, Kouzai Y, Tanaka J, Morita S, Sakamoto J, Sakamaki H, Inokuchi K. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy. Inter J Clin Oncol. 22(5):972-979, 2017.
Nosaka K, Iwanaga M, Imaizumi Y, Ishitsuka K, Ishizawa K, Ishida Y, Amano M, Ishida T, Uike N, Utsunomiya A, Ohshima K, Kawai K, Tanaka J, Tokura Y, Tobinai K, Watanabe T, Uchimaru K, Tsukasaki K. Epidemiological and clinical features of adult T-cell leukemia-lymphoma in Japan, 2010-2011: A nationwide survey. Cancer Sci. 108(12):2478-2486, 2017.
Nishiwaki S, Imai K, Mizuta S, Kanamori H, Ohashi K, Fukuda T, Onishi Y, Takahashi S, Uchida N, Eto T, Nakamae H, Yujiri T, Mori S, Nagamura-Inoue T, Suzuki R, Atsuta Y, Tanaka J. Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the Adult ALL WG of the JSHCT. Bone Marrow Transplant. 51(1):43-50, 2016.
Arima N, Nakamura F, Yabe T, Tanaka J, Fuji S, Ohashi K, Fukuda T, Miyamura K, Iwato K, Eto T, Mori T, Kobayashi N, Hoshino T, Kato C, Kanamori H, Nakamae H, Atsuta Y, Morishima Y, Kanda Y. Influence of differently licensed KIR2DL1-positive natural killercells in transplant recipients with acute leukemia: a Japanese national registry study. BBMT 22(3):423-431, 2016.
Mori J, Ishiyama K, Yamaguchi T, Tanaka J, Uchida N, Kobayashi T, Fukuda T, Kanamori H, Miyamura K, Takahashi S, Eto T, Hirokawa H, Mori S, Nagamura T, Atsuta Y, Takami A. Outcomes of allogeneic hematopoietic cell transplantation for patients with biphenotypic acute leukemia. Annals of Hematol. 95:295-300, 2016.
Muroi K, Miyamura K, Okada M, Yamashita T, Murata M, Ishikawa T, Uike N, Hidaka M, Kobayashi R, Imamura M, Tanaka J, Ohashi K, Taniguchi S, Ikeda T, Eto T, Mori M, Yamaoka M, Ozawa K. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study. Int J Hematol. 103(2):243-250, 2016.
Mizutani M, Hara M, Fujita H, Aoki J, Kanamori H, Ohashi K, Usuki K, Fukuda T, Chou T, Tanaka J, Atsuta Y, Takami A. Comparable outcomes between autologous and allogeneic transplant for adult acute myeloid leukemia in first complete remission. BMT 51(5):645-653, 2016.
Isono N, Imai Y, Watanabe A, Moriya K, Tamura H, Inokuchi K, Asano C, Masuda M, Shimura H, Mitsuhashi K, Kazama H, Sugimori H, Motoji T, Tanaka J. Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine. Leukemia and Lymphoma 57(9):2204-2207, 2016.
Mitsuhashi K, Kako S, Shigematsu A, Atsuta Y, Doki N, Fukuda T, Kanamori H, Onizuka M, Takahashi S, Ozawa Y, Kurokawa M, Inoue Y, Nagamura-Inoue T, Morishima Y, Mizuta S, Tanaka J. Comparison of cyclophosphamide combined with TBI, oral busulfan, or intravenous busulfan for allogeneic transplantation in adult patients with ALL. BBMT 22: 2194-2200, 2016.
Kogiso T, Hashimoto E, Ito T, Hara T, Ikarashi Y, Kodama K, Taniai M, Torii N, Yoshinaga K, Morita S, Takahashi Y, Tanaka J, Sakai S, Yamamoto M, Tokushige K. Successful Treatment of Ascites using a DenverR Peritoneovenous Shunt in a Patient with Paroxysmal Nocturnal Hemoglobinuria and Budd-Chiari syndrome. Intern Med. 55(20):2957-2963, 2016.
Mori N, Ohwashi M, Yoshinaga K, Okada M, Shiseki M, Tanaka J. Translocation (9;12)(q34.1;p13.?3) resulted in ETV6-ABL1 fusion in a patient with Philadelphia chromosome negative chronic myelogenous leukemia. Acta Haematologica 136:240?243, 2016.
Imai Y, Ohta E, Takeda S, Sunamura S, Ishibashi M, Tamura H, Wang Y, Deguchi A, Tanaka J, Maru Y, and Motoji T. Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma. JCI insight 1(5): e85061, 2016.
Tsukune Y, Sasaki M, Odajima T, Isoda A, Matsumoto M, Koike M, Tamura H, Moriya K, Ito S, Asahi M, Imai Y, Tanaka J, Handa H, Koiso H, Tanosaki S, Hua J, Hagihara M, Yahata Y, Suzuki S, Watanabe S, Sugimori H, Komatsu N. Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents' era. Ann Hematol. 95(9):1465-1472, 2016.
Arai Y, Kondo T, Shigematsu A, Tanaka J, Takahashi S, Kobayashi T, Uchida N, Onishi Y, Ishikawa J, Kanamori H, Sawa M, Yokota Y, Kouzai Y, Takanashi M, Ichinohe T, Atsuta Y, Mizuta S. High-dose cytarabine added to CY/TBI improves the prognosis of cord blood transplantation for acute lymphoblastic leukemia in adults: a retrospective cohort study. Bone Marrow Transplant. 2016 Dec;51(12):1636-1639.
Imai Y, Maru Y, Tanaka J. Clinical usage and mechanism of action for histone deacetylase inhibitors in the treatment of hematological malignancies. Cancer Science 107(11):1543-1549, 2016.
■和文論文
志関雅幸、田中淳司：慢性難治性DICの診断と治療のポイントとは？ Thrombosis Medicine 6:80-83, 2016.
Aoki K, Ishikawa T, Ishiyama K, Aoki J, Itonaga H, Fukuda T, Kakihana K, Uchida N, Ueda Y, Eto T, Mori T, Kondo T, Iwato K, Morishima Y, Tanaka J, Atsuta Y, Miyazaki Y. Conditioning Regimen in Allogeneic Transplantation for Elderly Patients with Advanced Myelodysplastic Syndromes. Br J Haematol. 168:463-466, 2015.
Shiseki M, Masuda A, Yoshinaga K, Mori N, Okada M, Motoji T, Tanaka J. Identification of the SOX5 gene as a novel IGH-involved translocation partner in BCL2-negative follicular lymphoma with t(12;14)(p12.2;q32). Int J Hematol. 102(5):633-638, 2015.
Takahata M, Hashino S, Nishio M, Sugita J, Shigematsu A, Onozawa M, Fujimoto K, Endo T, Kondo T, Tanaka J, Imamura M, Teshima T. Occurrence of adverse events caused by valganciclovir as preemptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration. Transpl Infect Dis. 17(6):810-815, 2015. doi: 10.1111/tid.12456.
Nishiwaki S, Imai K, Mizuta S, Kanamori H, Ohashi K, Fukuda T, Onishi Y, Takahashi S, Uchida N, Eto T, Nakamae H, Yujiri T, Mori S, Nagamura-Inoue T, Suzuki R, Atsuta Y, Tanaka J.Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the Adult ALL WG of the JSHCT.Bone Marrow Transplant. 51(1):43-50, 2016. doi: 10.1038/bmt.2015.217.
Arima N, Nakamura F, Yabe T, Tanaka J, Fuji S, Ohashi K, Fukuda T, Miyamura K, Iwato K, Eto T, Mori T, Kobayashi N,Hoshino T, Kato C, Kanamori H, Nakamae H, Atsuta Y, Morishima Y, Kanda Y. Influence of differently licensed KIR2DL1-positive natural killercells in transplant recipients with acute leukemia: a Japanese national registry study. BBMT 22(3):423-431, 2016. doi: 10.1016/j.bbmt.2015.09.029.
Mori J, Ishiyama K, Yamaguchi T, Tanaka J, Uchida N,Kobayashi T, Fukuda T, Kanamori H, Miyamura K,Takahashi S, Eto1 T, Hirokawa H, Mori S, Nagamura T,Atsuta Y, Takami A. Outcomes of allogeneic hematopoietic cell transplantation for patients with biphenotypic acute leukemia. Annals of Hematol. 95:295-300, 2016.
Muroi K, Miyamura K, Okada M, Yamashita T, Murata M, Ishikawa T, Uike N, Hidaka M, Kobayashi R, Imamura M, Tanaka J, Ohashi K, Taniguchi S, Ikeda T, Eto T, Mori M, Yamaoka M, Ozawa K. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study. Int J Hematol. 103(2):243-250, 2016. doi: 10.1007/s12185-015-1915-9.
Mizutani M, Hara M, Fujita H, Aoki J, Kanamori H, Ohashi K, Usuki K, Fukuda T, Chou T, Tanaka J, Atsuta Y, Takami A. Comparable outcomes between autologous and allogeneic transplant for adult acute myeloid leukemia in first complete remission. BMT (in press) doi: 10.1038/bmt.2015.349.
Isono N, Imai Y, Watanabe A, Moriya K, Tamura H, Inokuchi K, Asano C, Masuda M, Shimura H, Mitsuhashi K, Kazama H, Sugimori H, Motoji T, Tanaka J. Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine. Leukemia and Lymphoma (in press)
Ishihara H, Shimizu T, Unagami K, Hirai T, Toki D, Omoto K, Okumi M, Imai Y, Ishida H, and Tanabe K. Post-transplant lymphoproliferative disorder in kidney transplant recipients: a single-center experience in Japan. Ther Apher Dial in press
Uni M, Yoshimi A, Yamazaki S, Taoka K, Shinohara A, Nannya Y, Nakamura F, Kurokawa M. Comparison of garenoxacin with levofloxacin as antimicrobial prophylaxis in acute myeloid leukemia. Jpn J Clin Oncol. 2015 Aug;45(8):745-8. PMID: 25989991
Ueda R, Fuji S, Mori S, Hiramoto N, Hashimoto H, Tanaka T, Tada K, Kobayashi Y, Morikawa N, Shinohara A, Okinaka K, Maeshima AM, Kurosawa S, Kim SW, Yamashita T, Fukuda T. Characteristics and outcomes of patients diagnosed with norovirus gastroenteritis after allogeneic hematopoietic stem cell transplantation based on immunochromatography. Int J Hematol. 2015 Jul;102(1):121-8.PMID: 25930664
Higo T, Miyagaki T, Nakamura F, Shinohara A et al., Paraneoplastic pemphigus occurring after bendamustine and rituximab therapy for relapsed follicular lymphoma. Ann Hematol. 2015 Apr;94(4):683-5.
Takeshi Odajima, Minoko Takanashi, Hiroki Sugimori, Taiko Tanba, Kentaro Yoshinaga, Mutsuhiko Minami, Toshiko Motoji. Impact of Elevated Hemoglobin and Serum Protein on Vasovagal Reaction from Blood Donation. PLOS ONE 2016 Feb19:10.1371
Kobayashi R, Tanaka J, Hashino S, Ota S, Torimoto Y, Kakinoki Y, Yamamoto S, Kurosawa M, Hatakeyama N, Haseyama Y, Sakai H, Sato K, Fukuhara T. Etoposide-containing conditioning regimen reduces the occurrence of hemophagocytic lymphohistiocytosis after SCT. Bone Marrow Transplant. 49(2):254-257, 2014.
Hayase E, Fujimoto K, Mitsuhashi T, Hatanaka Y, Yoshida M, Takemura R, Iwasaki J, Shiratori S, Sugita J, Kondo T, Tanaka J, Imamura M, Matsuno Y, Teshima T. Epstein-barr virus-associated smooth muscle tumors after bone marrow transplantation. Transplantation. 2014 Jan 15;97(1):e1-5. doi: 10.1097/01.TP.0000437912.60638.23.
Shono Y, Shiratori S, Kosugi-Kanaya M, Ueha S, Sugita J, Shigematsu A, Kondo T, Hashimoto D, Fujimoto K, Endo T, Nishio M, Hashino S, Matsuno Y, Matsushima K, Tanaka J, Imamura M, Teshima T. Bone Marrow Graft-versus-Host Disease: Evaluation of Its Clinical Impact on Disrupted Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 20(4):495-500, 2014.
Mizuta S, Matsuo K, Imai K, Nishiwaki S, kanamori H, Ohashi K, Fukuda T, Onishi Y, Miyamura K, Takahashi S, Onizuka M, Suzuki R, Atsuta Y, Morishima Y, Kato K, Sakamaki H, Tanaka J. Pre-transplant administration of imatinib for allogeneic hematopoietic stem cell transplantation in patients with BCR-ABL-positive acute lymphoblastic leukemia. Blood 123(15):2325-2332, 2014.
Sano H, Kobayashi R, Tanaka J, Hashino S, Ota S, Torimoto Y, Kakinoki Y, Yamamoto S, Kurosawa M, Hatakeyama N, Haseyama Y, Sakai H, Sato K, Fukuhara T. Risk factor analysis of non-Hodgkin lymphoma-associated haemophagocytic syndromes: a multicentre study. Br J Haematol. 165(6):786-792, 2014.
Kato H, Kawase T, Kako S, Mizuta S, Kurokawa M, Mori M, Ohashi K, Iwato K, Miyamura K, Hidaka M, Sakamaki H, Suzuki R, Morishima Y, Tanaka J. Analysis of outcomes following autologous transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia during the first complete remission. Haematologica. 99(11):e228-30, 2014. doi: 10.3324/haematol.2014.108712.
Takami A, Yano S, Yokoyama H, Kuwatsuka Y, Yamaguchi T, Kanda Y, Morishima Y, Fukuda T, Miyazaki Y, Nakamae H, Tanaka J, Atsuta Y,1 Kanamori H. Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A retrospective analysis by the Adult AML Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant.20(11):1785-1790,2014.
Takahata M, Hashino S, Onozawa M, Shigematsu A, Sugita J, Fujimoto K, Endo T, Kondo T, Tanaka J, Imamura M, Teshima T. Hepatitis B virus (HBV) reverse seroconversion (RS) can be prevented even in non-responders to hepatitis B vaccine after allogeneic stem cell transplantation: long-term analysis of intervention in RS with vaccine for patients with previous HBV infection. Transpl Infect Dis. 2014 16(5):797-801.
Kanda J, Fuji S, Kato S, Takami A, Tanaka J, Miyamura K, Ohashi K, Takahiro Fukuda2, Ozawa Y, Kanamori H, Eto T, Kobayashi N, Iwato K, Morishima Y, Sakamaki H, Atsuta Y, Kanda Y. Decision Analysis for Donor 1 Selection in Stem Cell Transplantation ?2 HLA-8/8 Allele-Matched Unrelated Donor vs. HLA-1 AG Mismatched Related Donor. Blood Cancer J. 2014. Dec 5;4:e263. 1-9. doi: 10.1038/bcj.2014.85.
Shiozaki H, Yoshinaga K, Kondo T, Imai Y, Shiseki M, Mori N, Teramura M, Motoji T / Donor cell-derived leukemia after cord blood transplantation and a review of the literature: differences between cord blood and BM as the transplant source. - Bone Marrow Transplant 49: (102-109), 2014
Shinohara A, Imai Y, Nakagawa M, Takahashi T, Ichikawa M, Kurokawa M / Intracellular reactive oxygen species mark and influence the megakaryocyte-erythrocyte progenitor fate of common myeloid progenitors. - Stem Cells 32: (548-557), 2014
Kazama H, Teramura M, Kurihara K, Yoshinaga K, Kato T, Motoji T. Peroxiredoxin 2 expression is increased in neutrophils of patients with refractory cytopenia with multilineage dysplasia. Br J Haematol. 166: 720-728, 2014
Tochihara M, Kasai M, Katsumata Y, Sato E, Ishiguro N, Kazama H, Sugimoto N, Ichida H, Kawaguchi Y, YamanakaH. Erythematosus plaques with macrophage infi ltration as an initial manifestation of macrophage activation syndrome in a patient with systemic lupus erythematosus. Mod Rheumatol, DOI: 10.3109/14397595.2014.932042
Takaoka K, Nannya Y, Shinohara A et al., A novel scoring system to predict the incidence of invasive fungal disease in salvage chemotherapies for malignant lymphoma., Ann Hematol. 2014 Oct;93(10):1637-44.
Nasu R, Nannya Y, Shinohara A et al., Favorable outcomes of tacrolimus compared with cyclosporine A for GVHD prophylaxis in HSCT for standard-risk hematological diseases., Annals of Hematology., 93(7), 1215-23, 2014
Nannya Y, Shinohara A et al., Serial profile of vitamins and trace elements during the acute phase of allogeneic stem cell transplantation., Biology of Blood and Marrow Transplantation., 20(3), 430-4, 2014
Hiramoto N, Kurosawa S, Tajima K, Okinaka K, Tada K, Kobayashi Y, Shinohara A et al. , Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single-center analysis of 115 patients., Europian Journal of Haematology, 92(2), 137-46, 2014
Tanaka J, Kanamori H, Nishiwaki S, Ohashi K, Taniguchi S, Eto T, Nakamae H, Minagawa K, Miyamura K, Sakamaki H, Morishima Y, Kato K, Suzuki R, Nishimoto N, Oba K, Masauzi N. Reduced-intensity versus myeloablative conditioning allogeneic hematopoietic stem cell transplantation for patients aged over 45 years with acute lymphoblastic leukemia (ALL) in remission: A study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). Bone Marrow Transplant. 48:1389-1394, 2013.
Nishiwaki S, Miyamura K, Ohashi K, Kurokawa M, Taniguchi S, Fukuda T, Ikegame K, Takahashi S, Mori T, Imai K, Iida H, Hidaka M, Sakamaki H, Morisima Y, Kato K, Suzuki R, Tanaka J. Impact of donor source on adult Philadelphia chromosome-negative acute lymphoblastic leukemia: a retrospective analysis from the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Ann Oncology. 24:1594-1602, 2013.
Kurosawa S, Yakushijin K, Yamaguchi T, Atsuta Y, Nagamura-Inoue T, Akiyama H, Taniguchi S, Miyamura K, Takahashi S, Eto T, Ogawa H, Kurokawa M, Tanaka J, Kawa K, Kato K, Suzuki R, Morishima Y, Sakamaki H, Fukuda T. Recent decrease in non-relapse mortality due to GVHD and infection after allogeneic hematopoietic cell transplantation in non-remission acute leukemia. Bone Marrow Transplant. 48:1198-1204, 2013.
Nishiwaki S, Atsuta Y, Tanaka J. Allogeneic hematopoietic cell transplantation from alternative sources for adult Philadelphia chromosome-negative acute lymphoblastic leukemia: What should we choose when no HLA-matched related donor is available? Bone Marrow Transplant. 48:1369-1376, 2013.
Mitsuhashi K, Momose M, Masuda A, Tsunemi Y, Motoji T: Positron emission tomography revealed diffuse involvement of the lower legs and occult extracutaneous lesions in subcutaneous panniculitis-like T-cell lymphoma. Clin Nucl Med 38: 209-211, 2013
Shimura H, Imai Y, Ieko M, Shiseki M, Mori N, Teramura M, Motoji T: Transient lupus anticoagulant with a prolonged activated partial thromboplastin time secondary to cytomegalovirus-related infectious mononucleosis. Ann Hematol 92: 143-144, 2013
Wakao H, Yoshikiyo K, Koshimizu U, Furukawa T, Enomoto K, Matsunaga T, Tanaka T, Yasutomi Y, Yamada T, Minakami H, Tanaka J, Oda A, Sasaki T, Wakao R, Lantz O, Udagawa T, Sekiya Y, Higuchi K, Harada N, Nishimura K, Ohtaka M, Nakanishi M, Fujita H. Expansion of Functional Human Mucosal-Associated Invariant T Cells via Reprogramming to Pluripotency and Redifferentiation. Cell Stem Cell. 12(5): 546-558, 2013.
Kanda J, Ichinohe T, Kato S, Uchida N, Terakura S, Fukuda T, Hidaka M, Ueda Y, Kondo T, Taniguchi S, Takahashi S, Nagamura-Inoue T, Tanaka J, Atsuta Y, Miyamura K, Kanda Y. Unrelated cord blood transplantation vs. related transplantation with HLA 1-antigen mismatch in the graft-versus-host direction. Leukemia 27(2): 286-294, 2013.
Kurosawa S, Yakushijin K, Yamaguchi T, Atsuta Y, Nagamura-Inoue T, Akiyama H, Taniguchi S, Miyamura K, Takahashi S, Eto T, Ogawa H, Kurokawa M, Morishima Y, Tanaka J, Sakamaki H, Fukuda T. Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia/myelodysplastic syndrome. Bone Marrow Transplant 48(4): 529-536, 2013.
Imahashi N, Suzuki R, Fukuda T, Kakihana K, Kanamori H, Eto T, Mori T, Kobayashi N, Iwato K, Sakura T, Ikegame K, Kurokawa M, Kondo T, Iida H, Sakamaki H, Tanaka J, Kawa K, Morishima Y, Atsuta Y, Miyamura K. Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk acute myeloid leukemia in first complete remission. Bone Marrow Transplant 48(1): 56-62, 2013.
Kanamori H, Mizuta S, Kako S, Kato H, Nishiwaki S, Imai K, Shigematsu A, Nakamae H, Tanaka M, Ikegame K, Yujiri T, Fukuda T, Minagawa K, Eto T, Nagamura-Inoue T, Morishima Y, Suzuki R, Sakamaki H, Tanaka J. Reduced-intensity allogeneic stem cell transplantation for patients aged 50 years or older with B-cell ALL in remission: a retrospective study by the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplant. 48:1513-1518, 2013.
Tanaka J, Morishima Y, Takahashi Y, Yabe T, Oba K, Takahashi S, Taniguchi S, Ogawa H, Onishi Y, Miyamura K, Kanamori H, Aotsuka N, Kato K, Kato S, Atsuta Y, Kanda Y. Effects of KIR-ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission. Blood Cancer Journal 3, e164; 2013. doi:10.1038/bcj.2013.62.
Mori N, Ohwashi M, Yoshinaga K, Mitsuhashi K, Tanaka N, Teramura M, Okada M, Shiseki M, Tanaka J, Motoji T. L265P mutation of the MYD88 gene is frequent in Waldenstrom's macroglobulinemia and its absence in myeloma. PLoS One5;8(11):e80088. 2013, doi: 10.1371.
Shinohara A, Yoshiki Y, Masamoto Y et al., Moxifloxacin is more effective than tosufloxacin in reducing chemotherapy-induced febrile neutropenia in patients with hematological malignancies., Leukeimia Lymphoma, 54(4), 794-8、2013
Toya T, Shinohara A et al., A case of Schizophyllum commune sinusitis following unrelated cord blood transplantation for acute lymphoblastic leukemia., International Journal of Hematology, 98(2), 261-3, 2013
Watanabe-Okochi N, Yoshimi A, Sato T, Ikeda T, Kumano K, Taoka K, Satoh Y, Shinohara A et al., The shortest isoform of C/EBPβ, liver inhibitory protein (LIP), collaborates with Evi1 to induce AML in a mouse BMT model., Blood, 121(20), 4142-55, 2013
岡村隆光?増田道彦?寺村正尚?泉二登志子: Activation of Retinoic Acid Receptor α is Important for the Anti-myeloma Effect of Retinoids: New Therapeutic Approach Using Receptor Selective Retinoids for Multiple Myeloma. 東京女子医科大学雑誌 83: E576-E584
Watanabe-Okochi N, Yoshimi A, Sato T, Ikeda T, Kumano K, Taoka K, Satoh Y, Shinohara A et al., The shortest isoform of C/EBPβ, Liver inhibitory protein (LIP), collaborates with Evi1 to induce AML in a mouse BMT model, 臨床血液, 54巻8号, 749-58, 2013年
2012年
■英文論文
Tanaka J, Sugita J, Shiratori S, Shigematsu A, Imamura M. Dasatinib enhances the expansion of CD56+CD3- NK cells from cord blood. Blood 119: 6175-6176, 2012.
Tanaka J, Sugita J, Shiratori S, Shigematsu A, Asanuma S, Fujimoto K, Nishio M, Kondo T, Imamura M. Expansion of NK cells from cord blood with antileukemic activity using GMP-compliant substances without feeder cells. Leukemia 26: 1149-1152, 2012.
Kanda J, Saji H, Fukuda T, Kobayashi T, Miyamura K, Eto T, Kurokawa M, Kanamori H, Mori T, Hidaka M, Iwato K, Yoshida T, Sakamaki H, Tanaka J, Kawa K, Morishima Y, Suzuki R, Atsuta Y, Kanda Y. Related transplantation with HLA 1-antigen mismatch in the graft-versus-host direction and HLA 8/8-allele-matched unrelated transplantation: A nationwide retrospective study. Blood 119: 2409-2416, 2012.
Kashiwazaki H, Matsushita T, Sugita J, Shigematsu A, Kasashi K, Yamazaki Y, Kanehira T, Yamamoto S, Kondo T, Endo T, Tanaka J, Hashino S, Nishio M, Imamura M, Kitagawa Y, Inoue N. Professional oral health care reduces oral mucositis and febrile neutropenia in patients treated with allogeneic bone marrow transplantation. Support Care Cancer. 20: 367-373,2012.
Sugita J, Matsushita T, Kashiwazaki H, Kosugi M, Takahashi S, Wakasa K, Shiratori S, Ibata M, Shono Y, Shigematsu A, Obara M, Fujimoto K, Endo T, Nishio M, Kondo T, Hashino S, Tanaka J, Asaka M, Imamura M. Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD. Bone Marrow Transplant. 47: 258-264.2012.
Kashiwazaki H, Matsushita T, Sugita J, Shigematsu A, Kasashi K, Yamazaki Y, Kanehira T, Kondo T, Endo T, Tanaka J, Hashino S, Nishio M, Imamura M, Kitagawa Y, Inoue N. A comparison of oral mucositis in allogeneic hematopoietic stem cell transplantation between conventional and reduced-intensity regimens. Support Care Cancer. 20: 933-939, 2012.
Tsutsumi Y, Ogasawara R, Ito S, Sasaki J, Morita A, Senoo N, Murata N, Tanaka J, Asaka M, Imamura M.Retrospective analysis of an efficient peripheral blood stem cell collection and the relation between infused cell dose and clinical outcome in patients with malignant lymphoma and multiple myeloma. Int J Lab Hematol. 34: 403-409, 2012.
Tsutsumi Y, Ogasawara R, Miyashita N, Tanaka J, Asaka M, Imamura M. HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine. Int J Hematol. 95: 588-591, 2012
Toubai T, Tanaka J, Paczesny S, Shono Y, Reddy P, Imamura M. Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD)- Are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (allo-HCT) Curr Stem Cell Res Ther. 7: 229-239, 2012.
Matsukawa T, Goto H, Takahashi K, Asanuma S, Yasumoto A, Takahata M, Shigematsu A, Endo T, Tanaka J, Hashino S, Tanaka S, Imamura M. A fatal case of cytomegalovirus ventriculoencephalitis in a mycosis fungoides patient who received multiple umbilical cord blood cell transplantations. Int J Hematol 95:217-222, 2012.
Matsukawa T, Goto H, Takahashi K, Asanuma S, Yasumoto A, Takahata M, Shigematsu A, Endo T, Tanaka J, Hashino S, Tanaka S, Imamura M. A fatal case of cytomegalovirus ventriculoencephalitis in a mycosis fungoides patient who received multiple umbilical cord blood cell transplantations. Int J Hematol 95(2): 217-222, 2012.
Matsukawa T, Shigematsu A, Hayasaka K, Fujisawa S, Asanuma S, Yasumoto A, Goto H, Takahata M, Endo T, Tanaka J, Hashino S, Shimizu C, Imamura M.Chimerism analyses by sex-chromosome analysis confused relapse with donor cell leukemia after sex-mismatched allo-SCT. Bone Marrow Transplant 47(12): 1583-1584, 2012.
Okada K, Higashiyama A, Takahata M, Onozawa M, Kahata K, Ando S, Tanaka J, Hashino S, Imamura M. Complete remission following chemotherapy with low-dose cytosine arabinoside and macrophage colony-stimulating factor/granulocyte colony-stimulating factor in a patient with relapsed acute myeloid leukemia after stem cell transplantation. Intern Med 51(20): 2937-2941, 2012.
Yoshimi M, Goyama S, Kawazu M, Nakagawa M, Ichikawa M, Imai Y, Kumano K, Asai T, Mulloy JC, Kraft AS, Takahashi T, Shirafuji N, and Kurokawa M. Multiple phosphorylation sites are important for RUNX1 activity in early hematopoiesis and T-cell differentiation. European Journal of Immunology 42: 1044-1050, 2012.
Taoka K, Kumano K, Nakamura F, Hosoi M, Goyama S, Imai Y, Hangaishi A, Kurokawa M. The effect of iron overload and chelation on erythroid differentiation. International Journal of Hematology 95: 149-159, 2012.
Ainoda Y, Hirai Y, Fujita T, Isoda N, Totsuka K: Analysis of clinical features of non-HIV Pneumocystis jirovecii pneumonia. J Infect Chemother 18: 722-728, 2012
Hirai Y, Yamamoto A, Yaguchi A, Totsuka K: Lockjaw occurring after attending a small kitchen garden. Intern Med 51: 2991, 2012
Ohnishi K, Nakaseko C, Takeuchi J, Fujisawa S, Nagai T, Yamazaki H, Tauchi T, Imai K, Mori N, Yagasaki F, Maeda Y, Usui N, Miyazaki Y, Miyamura K, Kiyoi H, Ohtake S, Naoe T; Japan Adult Leukemia Study Group. Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study. Cancer Sci 103: 1071-1078, 2012
Ogata K, Kakumoto K, Matsuda A, Tohyama K, Tamura H, Ueda Y, Kurokawa M, Takeuchi J, Shibayama H, Emi N, Motoji T, Miyazaki Y, Tamaki H, Mitani K, Naoe T, Sugiyama H, Takaku F: Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: a multicenter validation study. Leuk Res 36: 1229-1236, 2012
Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi T, Usui N, Okamoto S, Ohe Y, Ohtake S, Kitamura K, Yamamoto M, Teshima H, Motoji T, Tamaki T, Sawada K, Ohyashiki K: Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica 97: 903-906, 2012
Ueda Y, Mizutani C, Nannya Y, Kurokawa M, Kobayashi S, Takeuchi J, Tamura H, Ogata K, Dan K, Shibayama H, Kanakura Y, Niimi K, Sasaki K, Watanabe M, Emi N, Teramura M, Motoji T, Kida M, Usuki K, Takada S, Sakura T, Ito Y, Ohyashiki K, Ogawa H, Suzuki T, Ozawa K, Imai K, Kasai M, Hata T, Miyazaki Y, Morita Y, Kanamaru A, Matsuda A, Tohyama K, Koga D, Tamaki H, Mitani K, Naoe T, Sugiyama H, Takaku F: Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes. Leuk Lymphoma 2012 [Epub ahead of print]
Hirai Y, Yoshihara T, Motoji T, Totsuka K: Facial-oropharyngeal Kaposi Sarcoma in a HIV-seropositive man. Intern Med 51: 2989-2990, 2012
Takanashi M, Odajima T, Aota S, Sudoh M, Yamaga Y, Ono Y, Yoshinaga K, Motoji T, Matsuzaki K, Satake M, Sugimori H, Nakajima K: Risk factor analysis of vasovagal reaction from blood donation. Transfus Apher Sci 47: 319-325, 2012.
Okada M, Suto Y, Hirai M, Shiseki M, Usami A, Okajima K, Teramura M, Mori N, Motoji T: Microarray CGH analyses of chromosomal 20q deletions in patients with hematopoietic malignancies. Cancer Genet 205: 18-24, 2012.
Tsuji K, Wang YH, Takanashi M, Odajima T, Lee GA, Sugimori H, Motoji T. Overexpression of lung resistance-related protein and P-glycoprotein and response to induction chemotherapy in acute myelogenous leukemia. Hematol Rep 4: e18, 2012.
Mori N, Totsuka K, Ishimori N, Yoshinaga K, Teramura M, Noguchi S, Oda H, Motoji T: Acquired Hemophilia A in a Patient with Essential Thrombocythemia. Acta Haematol 127: 170-172, 2012
Shimura H, Mori N, Wang YH, Okada M, Motoji T: Aberrant methylation and decreased expression of the RIZ1 gene are frequent in adult acute lymphoblastic leukemia of T cell phenotype. Leuk Lymphoma 53: 1599-1609, 2012
Mitsuhashi K, Ishiyama M, Imai Y, Shiseki M, Mori N, Teramura M, Seshimo A, Motoji T: Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy. Br J Haematol 158: 798-800, 2012
Kazama H, Teramura M, Yoshinaga K, Masuda A, Motoji T: Long-term remission of primary bone marrow diffuse large B-cell lymphoma treated with high-dose chemotherapy rescued by in vivo rituximab-purged autologous stem cells. Case Report Med 2012: 957063, 2012.
Teramura M, Ishiyama M, Kazama H, Yoshinaga K, Shiseki M, Mori N, Motoji T: Comparison of High-Dose Dexamethasone and Prednisone for Initial Treatment of Adult Primary Immune Thrombocytopenia. Open J Blood Diseases 2: 85-89, 2012
Asanuma S, Tanaka J, Sugita J, Kosugi M, Shiratori S, Wakasa K, Shono Y, Shigematsu A, Kondo T, Kobayashi T, Asaka M, Imamura M. Expansion of CD4+ CD25+ regulatory T cells from cord blood CD4+ cells using the common γ-chain cytokines (IL-2 and IL-15) and rapamycin. Ann Hematol 90: 617-624, 2011.
Tsutsumi Y, Ito S, Ogasawara R, Kudo K, Tanaka J, Asaka M, Imamura M. HCV virus and lymphoid neoplasms. Adv Hematol. 2011: 717951. Epub 2011 Jul 5.
Hayakawa S, Shiratori S, Yamato H, Kameyama T, Kitatsuji C, Kashigi F, Goto S, Kameoka S, Fujikura D, Yamada T, Mizutani T, Kazumata M, Sato M, Tanaka J, Asaka M, Ohba Y, Miyazaki T, Imamura M, *Takaoka A. ZAPS is a potent stimulator of signaling mediated by the RNA helicase RIG-I during antiviral responses. Nature Immunol 12: 37-44, 2011.
Kobayashi T, Ishida J, Musashi M, Ota S, Yoshida T, Shimizu Y, Chuma M, Kawakami H, Asaka M, Tanaka J, Imamura M, Kobayashi M, Itoh H, Edamatsu H, Sutherland LC, Brachmann RK. p53 transactivation is involved in the antiproliferative activity of the putative tumor suppressor RBM5. Int J Cancer. 128: 304-318, 2011.
Inamoto Y, Miyamura K, Okamoto S, Akiyama H, Iida H, Eto T, Morishima Y, Kawa K, Kikuchi A, Nagatoshi Y, Tanaka J, Ashida T, Hirokawa M, Tsuchida M, Mori S for the Japan Marrow Donor Program. Disease stage stratified effects of cell dose in unrelated bone marrow transplantation for hematological malignancies: A report from Japan Marrow Donor Program. Bone Marrow Transaplant 46:1192-1202, 2011.
Onozawa M, Ohmura K, Ibata M, Iwasaki J, Okada K, Kasahara I, Yamaguchi K, Kubota K, Fujisawa S, Shigematsu A, Endo T, Kondo T, Hashino S, Tanaka J, Matsuno Y, Asaka M, Imamura M. The 8p11 myeloproliferative syndrome due to rare FGFR1OP2-FGFR1 fusion. Eur J Haematol 86: 347-349, 2011.
Iida M, Fukuda T, Ikegame K, Yoshihara S, Ogawa H, Taniguchi S, Takami A, Abe Y, Hino M, Etou T, Ueda Y, Yujiri T, Matsui T, Okamura A, Tanaka J, Atsuta Y, Kodera Y, Suzuki R. Use of mycophenolate mofetil in patients received allogeneic hematopoietic stem cell transplantation in Japan. Inter J Hematol 93:523-531, 2011.
Shigematsu A, Tanaka J, Suzuki R, Atsuta Y, Kawase T, Ito YM, Yamashita T, Fukuda T, Kumano K, Iwato K, Yoshiba F, Kanamori H, Kobayashi N, Fukuhara T, Morishima Y, Imamura M. Outcome of medium-dose VP-16/CY/TBI superior to CY/TBI as a conditioning regimen for allogeneic stem cell transplantation in adult patients with acute lymphoblastic leukemia. Int J Hematol 94: 463-471, 2011.
Shono Y, Kosugi-Kanaya M, Shiratori S, Sugita J, Fujimoto K, Kondo T, Nishio M, Tanaka J, Imamura M. Donor cell leukemia after umbilical cord blood transplantation: recurrent or de novo? The importance of diagnosis for therapeutic decision making. Int J Hematol 93: 563-565, 2011.
Shiratori S, Kondo T, Fujisawa S, Kubota K, Kosugi M, Shono Y, Sugita J, Fujimoto K, Nishio M, Tanaka J, Koike T, Matsuno Y, Matsuno K, Asaka M, Imamura M. c-myc rearrangement in B-cell lymphoblastic lymphoma with the involvement of multiple extranodal lesions. Leuk Lymphoma 52: 716-718, 2011.
Arita K, Kondo T, Sugita J, Shigematsu A, Shiratori S, Wakasa K, Yasumoto A, Ibata M, Shono Y, Kikuchi M, Goto H, Takeda Y, Takahata M, Kato N, Nishio M, Ota S, Tanaka J, Imamura M. Sequential chemotherapy and myeloablative allogeneic hematopoietic stem cell transplantation for refractory acute lymphoblastic leukemia. Int J Hematol 94: 291-295, 2011.
Kataoka K, Sato T, Yoshimi A, Goyama S, Tsuruta T, Kobayashi H, Shimabe M, Arai S, Nakagawa M, Imai Y, Kumano K, Kumagai K, Kubota, N, Kadowaki T, and Kurokawa M. Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity. Journal of Experimental Medicine 208: 2403-2416, 2011.
Yoshiki Y, Asai T, Ichikawa M, Hangaishi A, Ota S, Imai Y, Takahashi T, and Kurokawa M. A Case of Myeloid Sarcoma with Correlation to JAK2V617F Mutation, Complicated by Myelofibrosis and Secondary Acute Myeloid Leukemia. Internal Medicine 50: 2649-2652, 2011.
Nakagawa M, Shimabe M, Watanabe-Okochi N, Arai S, Yoshimi A, Shinohara A, Nishimoto N, Kataoka K, Sato T, Kumano K, Nannya Y, Ichikawa M, Imai Y, and Kurokawa M. AML1/RUNX1 functions as a cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors. Blood 118: 6626-6637, 2011.
Nishimoto N, Arai S, Ichikawa M, Nakagawa M, Goyama S, Kumano K, Takahashi T, Kamikubo Y, Imai Y, and Kurokawa M. Loss of AML1/Runx1 accelerates the development of MLL-ENL leukemia through downregulation of p19ARF. Blood 118: 2541-2550, 2011.
Yoshizato T, Nannya Y, Yoshiki Y, Nakamura F, Imai Y, Ichikawa M, and Kurokawa M. Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia. International Journal of Hematology 93: 400-402, 2011.
Nannya Y, Kataoka K, Hangaishi A, Imai Y, Takahashi T, and Kurokawa M. The negative impact of female donor/male recipient combination in allogeneic hematopoietic stem cell transplantation depends on disease risk. Transplant International 24: 469-476, 2011.
Arai S, Yoshimi A, Shimabe A, Ichikawa M, Nakagawa M, Imai Y, Goyama S and Kurokawa M. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Blood 117: 6304-6314, 2011.
Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y, Nitta E, Arai S, Sato T, Shimabe M, Nakagawa M, Imai Y, Kitamura T, and Kurokawa M. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood 117: 3617-3628, 2011.
Kobayashi H, Ichikawa M, Hangaishi A, Imai Y, and Kurokawa M. Concurrent development of "Burkitt-like" lymphoma and BCL-2-rearranged low-grade B cell lymphoma sharing the same germinal center origin. International Journal of Hematology 93: 112-117, 2011.
Kobayashi CI, Yamamoto G, Hayashi A, Ota S, Imai Y, Fukayama M, and Kurokawa M. Fatal amebic colitis after high-dose dexamethasone therapy for newly diagnosed multiple myeloma. Annals of Hematology 90: 225-226, 2011.
Hirai Y, Ainoda Y, Nakamura-Uchiyama F, Umetani K, Totsuka K: Unusual colonoscopic view of Enterobius vermicularis. Intern Med 50: 657, 2011.
Kobayashi Y, Sakamaki H, Fujisawa S, Ando K, Yamamoto K, Okada M, Ishizawa K, Nagai T, Miyawaki S, Motoji T, Usui N, Iida S, Taniwaki M, Uoshima N, Seriu T, Ohno R: Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis. Int J Hematol 93: 745-749, 2011
Nagai H, Ogura M, Kusumoto S, Takahashi N, Yamaguchi M, Takayama N, Kinoshita T, Motoji T, Ohyashiki K, Kosugi H, Matsuda S, Ohnishi K, Omachi K, Hotta T: Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma. Eur J Haematol 86: 117-123, 2011
Hirai Y, Ainoda Y, Shoji T, Fujita T, Yoshinaga K, Shiseki M, Mori N, Teramura M, Totsuka K, Motoji T: Disseminated Cryptococcosis in a Non-Hodgkin's Lymphoma Patient with Late-Onset Neutropenia Following Rituximab-CHOP Chemotherapy: A Case Report and Literature Review. Mycopathologia 172: 227-232, 2011
Yamada O, Ozaki K, Furukawa T, Machida M, Wang YH, Motoji T, Mitsuishi T, Akiyama M, Yamada H, Kawauchi K, Matsuoka R: Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1. Cell Signal 23: 1119-1127, 2011.
Shiseki M, Masuda A, Watanabe N, Fujii M, Kimura T, Yoshinaga K, Mori N, Teramura M, Motoji T: Development of diffuse large B-cell lymphoma in a patient with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma: clonal identity between two B-cell neoplasms. Hematol Rep 3: e10, 2011
Mori N, Inoue K, Okada M, Motoji T: Absence of Mutations on the SNF5 Gene in Hematological Neoplasms with Chromosome 22 Abnormalities. Acta Haematol 126: 69-75, 2011
Tanaka N, Wang YH, Shiseki M, Takanashi M, Motoji T: Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells. Leuk Res 35: 1219-1225, 2011
Mori N, Yoshinaga K, Tomita K, Ohwashi M, Kondoh T, Shimura H, Wang YH, Shiseki M, Okada M, Motoji T: Aberrant methylation of the RIZ1 gene in myelodysplastic syndrome and acute myeloid leukemia. Leuk Res 35: 516-521, 2011
Hirai Y: Treatment Options for Gram-Positive and Gram-Negative Bacteria: Focus on Ceftriaxone. Clin Med Rev Ther 3: 215-234, 2011.
Nakagawa M, Shimabe M, Watanabe-Okochi N, Arai S, Yoshimi A, Shinohara A et al., AML1/RUNX1 functions as a cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors., Blood, 118(25), 6626-37, 2011
Kikuchi M, Tanaka J, Kondo T, Hashino S, Kasai M, Kurosawa M, Iwasaki H, Morioka M, Kawamura T, Masauzi N, Fukuhara T, Kakinoki Y, Kobayashi H, Noto S, Asaka M, Imamura M. Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia. Inter J Hematol 92: 481-489, 2010.
Tsutsumi Y, Ogasawara R, Kamihara Y, Ito S, Yamamoto Y, Tanaka J, Asaka M, Imamura M. Rituximab administration and reactivation of HBV. Hepat Res Treat. 2010;2010: 182067. Epub 2010 Dec 1.
Iwanaga M, Watanabe T, Utsunomiya A, Okayama A, Uchimaru K, Koh K, Ogata M, Kikuchi H, Sagara Y, Uozumi K, Mochizuki M, Tsukasaki K, Saburi Y, Yamamura M, Tanaka J, Moriuchi Y, Hino S, Kamihira S, Yamaguchi K. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood 116: 1211-1219, 2010.
Sugita J, Tanaka J, Yasumoto A, Hashimoto A, Shiratori S, Wakasa K, Kikuchi M, Shigematsu A, Kondo T, Asaka M, Imamura M. Differential effects of interleukin-12 and interleukin-15 on expansion of NK cell receptor-expressing CD8+ T cells. Ann Hematol 89: 115-120, 2010.
Kondo T, Yasumoto A, Arita K, Sugita J, Shigematsu A, Okada K, Takahata M, Onozawa M, Kahata K, Takeda Y, Obara M, Yamamoto S, Endo1 T, Nishio1 M, Sato N, Tanaka J, Hashino1 S, Koike T, Asaka M, Imamura M. Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation. Int J Hematol 91: 310-321, 2010.
Takahata M, Hashino S, Okada K, Onozawa M, Kahata K, Sugita J, Shigematsu A, Kondo T, Yamamoto S, Endo T, Nishio M, Ito Y, Tanaka J, Koike T, Asaka M, Imamura M. Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose TBI (Flu-BU2-TBI): clinical efficacy in high-risk patients. Am J Hematol 84: 243-248, 2010.
Shigematsu A, Yamamoto S, Sugita J, Kondo T, Onozawa M, Kahata K, Endo T, Shiratori S, Ota S, Yamaguchi K, Wakasa K, Takahata M, Goto H, Ito S, Takemura R, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M. Increased risk of bacterial infection after engraftment in patients treated with allogeneic bone marrow transplantation following reduced-intensity conditioning regimen. Transpl Infect Dis 12: 412-420, 2010.
Imai Y, Shimaoka M, and Kurokawa M. Essential roles of VLA-4 in the hematopoietic system. International Journal of Hematology, 91: 569-575, 2010.
Hosoi M, Ichikawa M, Imai Y and Kurokawa M. A case of anaplastic large cell lymphoma, ALK positive, primary presented in the skin and relapsed with systemic involvement and leukocytosis after years of follow-up period. International Journal of Hematology 92: 667-668, 2010.
Asano H, Imai Y, Ota S, Yamamoto G, Takahashi T, Fukayama M, and Kurokawa M. CD30-positive anaplastic variant diffuse large B cell lymphoma: a rare case presented with cutaneous involvement. International Journal of Hematology 92: 550-552, 2010.
Nakazaki K, Hangaishi A, Nakamura F, Hosoi M, Imai Y, Takahashi T, Nannya Y, and Kurokawa M. IgG-associated immune thrombocytopenia in Waldenstrom macroglobulinemia. International Journal of Hematology 92: 360-363, 2010.
Kataoka K, Seo S, Sugawara Y, Ota S, Imai Y, Takahashi T, Fukayama M, Kokudo N, and Kurokawa M. Post-transplant lymphoproliferative disorder after adult-to adult living donor liver transplant: case series and review of literature. Leukemia & Lymphoma 51: 1494-1501, 2010.
Nishimoto N, Imai Y, Ueda K, Nakagawa M, Shinohara A, Ichikawa M, Nannya Y, and Kurokawa M. T cell acute lymphoblastic leukemia arising from familial platelet disorder. International Journal of Hematology 92: 194-197, 2010.
Takahashi T, Hangaishi A, Yamamoto G, Ichikawa M, Imai Y, Kurokawa M. HIV-negative, HHV-8-unrelated primary effusion lymphoma-like lymphoma: report of two cases. American Journal of Hematology 85: 85-87, 2010.
Kagoya Y, Hangaishi A, Takahashi T, Imai Y, and Kurokawa M. High-dose dexamethasone therapy for severe thrombocytopenia and neutropenia induced by EBV infectious mononucleosis. International Journal of Hematology 91: 326-327, 2010.
Ueda K, Watadani T, Maeda E, Ota S, Kataoka K, Seo S, Kumano K, Hangaishi A, Takahashi T, Imai Y, Ohtomo K, Fukayama M, Nannya Y, and Kurokawa M. Outcome and treatment of late-onset noninfectious pulmonary complications after allogeneic haematopoietic SCT. Bone Marrow Trasnplantation 45: 1719-1727, 2010.
Ueda K, Nannya Y, Asai T, Yamamoto G, Hangaishi A, Takahasi T, Imai Y, and Kurokawa M. Efficacy and safety of modified rituximab-ESHAP therapy for relapsed/refractory B-cell lymphoma. Journal of Chemotherapy 22: 54-57, 2010.
Park EJ, Peixoto A, Imai Y, Goodarzi A, Cheng G, Carman CV, von Andrian UH, and Shimaoka M. Distinct roles for LFA-1 affinity regulation during T cell adhesion, diapedesis, and interstitial migration in lymph nodes. Blood 115: 1572-1581, 2010.
Goyama S, Nitta E, Yoshino T, Kako S, Watanabe-Okochi N, Shimabe M, Imai Y, Takahashi K, and Kurokawa M. EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization. Leukemia 24: 81-88, 2010.
Hosoi M, Yamamoto G, Imai Y, and Kurokawa M. Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma. Annals of Hematology 89: 207-208, 2010.
Masamoto Y, Imai Y, Seo S, Akahane M, and Kurokawa M. A case report of non-traumatic renal artery pseudoaneurysm due to chemotherapy for diffuse large B-cell lymphoma. Annals of Hematology 89: 107-108, 2010.
Hirai Y, Ainoda Y, Shoji T, Totsuka K: Ceftriaxone plus gentamicin or ceftriaxone alone for streptococcal endocarditis in Japanese patients as alternative first-line therapies. J Infect Chemother 16: 186-192, 2010
Nagai T, Takeuchi J, Dobashi N, Kanakura Y, Taniguchi S, Ezaki K, Nakaseko C, Hiraoka A, Okada M, Miyazaki Y, Motoji T, Higashihara M, Tsukamoto N, Kiyoi H, Nakao S, Shinagawa K, Ohno R, Naoe T, Ohnishi K, Usui N: Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in Japan. Int J Hematol 92: 111-117, 2010
Kobayashi S, Teramura M, Arai M, Masuda A, Mizoguchi H, Motoji T: Successful salvage treatment of blastic natural killer cell lymphoma with methotrexate. Int J Hematol 92: 634-637, 2010
Shinohara A, Ichikawa M, Ueda K et al., A novel MLL-AF1p/Eps15 fusion variant in therapy-related acute lymphoblastic leukemia, lacking the EH-domains. Leukemia Research、34(2)、e62-3、2010
Tanaka J, Sugita J, Asanuma S, Arita K, Shono Y, Kikutchi M, Shiratori S, Wakasa K, Yasumoto A, Shigematu A, Kondo T, Kobayashi T, Asaka M, Imamura M. Increased number of CD16+CD56dim NK cells in peripheral blood mononuclear cells after allogeneic cord blood transplantation. Human Immunol 70: 701-705, 2009.
Toubai T, Shono Y, Nishihira J, Ibata M, Suigita J, Kato N, Ohkawara T, Tone S, Lowler K, Ota S, Tanaka J, Asaka M, Reddy P, Imamura M. Serum macrophage migration inhibitory factor (MIF) levels after allogeneic hematopoietic stem cell transplantation. Int J Lab Hematol. 31: 161-168, 2009.
Tsutsumi Y, Ichiki K, Shiratori S, Kawamura T, Tanaka J, Asaka M, Imamura M, Masauzi N. Changes in hepatitis C virus antibody titer and viral RNA load in non-Hodgkin's lymphoma patients after rituximab chemotherapy. Int J Lab Hematol. 31: 468-470, 2009.
Tsutsumi Y, Shigematsu A, Hashino S, Tanaka J, Chiba K, Masauzi N, Kobayashi H, Kurosawa M, Iwasaki H, Morioka M, Asaka M, Imamura M. Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin's lymphoma in Hokkaido. Ann Hematol. 88: 375-377, 2009.
Shigematsu A, Yasumoto A, Yamamoto S, Sugita J, Kondo T, Onozawa M, Kahata K, Endo T, Ota S, Sato N, Takahata M, Okada K, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 15: 679-685, 2009.
Toubai T, Shono Y, Tone S, Ibata M, Kato N, Malter C, Lowler KP, Ota S, Tanaka J, Asaka M, Imamura M. Serum soluble tumor necrosis factor-related apoptosis-inducing ligand level after allogeneic hematopoietic cell transplantation. Leuk Lymphoma 50: 844-847, 2009.
Onozawa M, Hashino S, Haseyama Y, Hirayama Y, Iizuka S, Ishida T, Kaneda M, Kobayashi H, Kobayashi R, Koda K, Kurosawa M, Masauji N, Matsunaga T, Mori A, Mukai M, Nishio M, Noto S, Ota S, Sakai H, Suzuki N, Takahashi T, Tanaka J, Torimoto Y, Yoshida M, Fukuhara T. Incidence and risk of postherpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients: hokkaido hematology study group. Biol Blood Marrow Transplant 15: 724-729, 2009.
Kikuchi M, Okumura F, Tsukiyama T, Watanabe M, Miyajima N, Tanaka J, Imamura M, Hatakeyama S. TRIM24 mediates ligand-dependent activation of androgen receptor and is repressed by a bromodomain-containing protein, BRD7, in prostate cancer cells. Biochim Biophys Acta. Molecular Cell Research 1793: 1828-1836, 2009.
Tsutsumi Y, Yamamoto Y, Tanaka J, Asaka M, Imamura M, Masauzi N. Prevention of hepatitis B virus reactivation under rituximab therapy. Immunotherapy. 1: 1053-1061, 2009.
Imamura M, Tanaka J. Graft-versus-Leukemia Effect of Nonmyeloablative Stem Cell Transplantation. Korean J Intern Med 24: 287-298, 2009.
Toubai T, Paczesny S, Shono Y, Tanaka J, Lowler KP, Malter CT, Kasai M, Imamura M. Mesenchymal Stem Cells for Treatment and Prevention of Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Curr Stem Cell Res Ther. 4: 252-259, 2009.
Tsutsumi Y, Ito S, Ichiki K, Komatsu Y, Shiratori S, Kawamura T, Kudo K, Shimoyama N, Tanaka J, Asaka M, Imamura M, Masauzi N. Systemic amyloidosis complicated with peliosis. Ann Hematol. 88: 917-920, 2009.
Shimabe M, Goyama S, Watanabe-Okochi N, Yoshimi A, Ichikawa M, Imai Y, and Kurokawa M. Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and leukemic cells. Oncogene, 10: 4364-4374, 2009.
Yoshimi A, Asai T, Maeda D, Hangaishi A, Sakatani T, Takahashi T, Imai Y, Fukayama M, and Kurokawa M. Chronic myelomonocytic leukemia presenting severe uterine hemorrhage due to uterine infiltration of leukemic cells and early-stage endometrial adenocarcinoma. Archives of Gynecology and Obstetrics 280: 1077-1078, 2009.
Kataoka K, Ichikawa M, Hangaishi A, Takahashi T, Imai Y, and Kurokawa M. Interstitial pneumonia associated with progression of myelodysplastic syndrome. International Journal of Hematology 89: 718-719, 2009.
Ueda K, Nannya Y, Kumano K, Hangaishi A, Takahashi T, Imai Y, and Kurokawa M. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. International Journal of Hematology 89: 592-599, 2009.
Yoshimi M, Nannya Y, Watanabe T, Asai T, Ichikawa M, Yamamoto G, Kumano K, Hangaishi A, Imai Y, Takahashi T, Chiba S, and Kurokawa M. Acute eosinophilic pneumonia is a non-infectious lung complication after allogeneic hematopoietic stem cell transplantation. International Journal of Hematology 89: 244-248, 2009.
Yoshimi A, Nannya Y, Asano D, Yamamoto G, Kumano K, Hangaishi A, Matsui Y, Takahashi T, Imai Y, Kokudo N, and Kurokawa M. Successful haematopoietic stem cell transplantation from an HLA-identical sibling in a patient with aplastic anemia following HLA-haploidentical living-related liver transplantation for fulminant hepatitis. Biology of Blood and Marrow Transplantation 15: 389-390, 2009.
Kataoka K, Nannya Y, Hangaishi A, Imai Y, Chiba S, Takahashi T, and Kurokawa M. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation 15: 195-204, 2009.
Fumiya Miyamura, Shinichi Kato, Hiroko Yamagami, Ken Sato, Miki Sato, Kiriko Terasako, Shun-ichi Kimura, Hideki Nakasone, Satoko Aoki, Shinya Okuda, Rie Yamazaki, Kumi Oshima, Kentaro Yoshinaga, Takakazu Higuchi, Junji Nishida, Toshio Demitsu, Akihiro Kakehashi, Yoshinobu Kanda: Successful treatment of young-onset adult T cell leukemia/lymphoma and preceeding chronic refractory eczema and corneal injury by allogeneic hematopoietic stem cell transplantation. Int J Hematol 90: 397-401,2009
Sakamaki H, Ishizawa K, Taniwaki M, Fujisawa S, Morishima Y, Tobinai K, Okada M, Ando K, Usui N, Miyawaki S, Utsunomiya A, Uoshima N, Nagai T, Naoe T, Motoji T, Jinnai I, Tanimoto M, Miyazaki Y, Ohnishi K, Iida S, Okamoto S, Seriu T, Ohno R: Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol 89: 332-341, 2009
Wang YH, Takanashi M, Tsuji K, Tanaka N, Shiseki M, Mori N, Motoji T: Level of DNA topoisomerase IIα mRNA predicts the treatment response of relapsed acute leukemic patients. Leuk Res 33: 902-907, 2009
Ueda K, Yamamoto G, Shinohara A et al., Early onset of acute lymphoblastic leukemia with MLL rearrangement after autologous stem cell transplantation for multiple myeloma., Annals of Hematology, ;88(8), 813-4, 2009
Sugita J, Tanaka J, Hashimoto A, Shiratori S,Yasumoto A, Wakasa K, Kikuchi M, Shigematsu A, Miura Y, Tsutsumi Y, Kondo T, Asaka M, Imamura M. Influence of conditioning regimens and stem cell sources on donor-type chimerism early after stem cell transplantation. Ann Hematol 87: 1003-1008, 2008.
Sugita J, Iwao N, Tanaka J, Kato N, Shiratori S, Wakasa K, Shigematsu A, Toubai T, Takahata M, Kondo T, Asaka M, Imamura M. T cell receptor excision circle (TREC) levels in CD94-expressing CD8 T Cells during graft-versus-host disease. Leukemia Lymphoma 49: 1306-1310, 2008.
Sugita J, Tanaka J, Kurosawa M, Fukuhara T, Hashino S, Torimoto E, Koizumi K, Masauji N, Nishimura S, Koda K, Imamura M, Kasai M. Effects of the mean daily doses of imatinib during the first year on survival of patients with chronic myeloid leukemia (CML) in Japan: a study of the Hokkaido Hematology Study Group. Eur J Haematol. 80: 160-163, 2008.
Kaji M, Tanaka J, Sugita J, Kato N, Ibata M, Shono Y, Ota S, Kondo T, Asaka M, Imamura M. Ciprofloxacin inhibits lipopolysaccharide-induced toll-like receptor-4 and 8 expression on human monocytes derived from adult and cord blood. Ann Hematol 87: 229-231, 2008.
Shigematsu A, Kondo T, Yamamoto S, Sugita J, Onozawa M, Kahata K, Endo T, Shiratori S, Ota S, Obara M, Wakasa K, Takahata M, Takeda Y, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total body irradiation for adult patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant 14: 568-575, 2008.
Shiratori S, Yasumoto A, Tanaka J, Shigematsu A, Yamamoto S, Nishio M, Hashino S, Morita R, Takahata M, Onozawa M, Kahata K, Kondo T, Ota S, Wakasa K, Sugita J, Koike T, Asaka M, Kasai M, Imamura M. A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia/lymphoma (ATL): clinical impact of graft-versus-leukemia/lymphoma effect. Biol Blood Marrow Transplant 14: 817-823, 2008.
Imai Y, Park EJ, Peer D, Peixoto A, Cheng G, von Andrian UH, Carman CV, and Shimaoka M. Genetic perturbation of the putative cytoplasmic membrane-proximal salt bridge aberrantly activates α4 integrins. Blood 112: 5007-5015, 2008.
Kondo T, Mori A, Darmanin S, Hashino S, Tanaka J, Asaka M. The seventh pathogenic fusion gene FIP1L1-RARA was isolated from a t(4;17)-positive Acute Promyelocytic Leukemia. Haematologica 93: 1414-1416, 2008.
Onozawa M, Hashino S, Morita R, Takahata M, Shigematsu A, Kahata K, Kondo T, Tanaka J, Imamura M, Asaka M. HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection. Biol Blood Marrow Transplant 14: 1226-1230, 2008.
Shiratori S, Tsutsumi Y, Kawamura T, Kudo K, Shimoyama N, Masauzi N, Tanaka J, Asaka M, Imamura M. HCV non-structural protein 3 and HCV RNA genome in non-Hodgkin lymphoma and transition of the serum HCV RNA level: a retrospective analysis in one institution. Int J Hematol 87: 298-302, 2008.
Toubai T, Hirate D, Shono Y, Ota S, Ibata M, Mashiko S, Sugita J, Shigematsu A, Miura Y, Kato N, Umehara S, Kahata K, Tsutsumi Y, Iwao N, Toyoshima N, Tanaka J, Asaka M, Imamura M. Chimerism and T-cell receptor repertoire analysis after unrelated cord blood transplantation with a reduced-intensity conditioning regimen following autologous stem cell transplantation for multiple myeloma. Int J Lab Hematol 30: 75-81, 2008.
Imamura S, Uchiyama J, Koshimizu E, Hanai J, Raftopoulou C, Murphey RD, Bayliss PE, Imai Y, Burns CE, Masutomi K, Gagos S, Zon LI, Roberts TM, Kishi S. A non-canonical function of zebrafish telomerase reverse transcriptase is required for developmental hematopoiesis. PLoS ONE 3: e3364, 2008
Fujishima N, Sawada K, Hirokawa M, Oshimi K, Sugimoto K, Matsuda A, Teramura M, Karasawa M, Arai A, Yonemura Y, Nakao S, Urabe A, Omine M, Ozawa K: PRCA Collaborative Study Group. Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica 93: 1555-1559, 2008
Yamada O, Kawauchi K, Akiyama M, Ozaki K, Motoji T, Adachi T, Aizawa E: Leukemic cells with increased telomerase activity exhibit resistance to imatinib. Leuk Lymphoma 49: 1168-1177, 2008
Mori N, Yoshinaga K, Tada M, Wang YH, Shiseki M, Motoji T: Infrequent V617F mutation of the JAK2 gene in myeloid leukemia and its absence in lymphoid malignancies in Japan. Genetics and Molecular Biology 31: 427-430, 2008
Yoshinaga K, Mori N, Wang YH, Tomita K, Shiseki M, Motoji T: JAK2 V617F mutation is rare in idiopathic erythrocytosis : a difference from polycythemia vera. Int J Hematol 88: 82-87, 2008
Kitagawa Y, Sameshima Y, Shiozaki H, Ogawa S, Masuda A, Mori S, Teramura M, Masuda M, Kameoka S, Motoji T: Isolated granulocytic sarcoma of the small intestine successfully treated with chemotherapy and bone marrow transplantation. Int J Hematol 87: 410-413, 2008
Asano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A et al., Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation., International Journal of Hematology, 87(3), 310-8, 2008
１４）Asano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A et al., Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation., American Journal of Hematology, 83(6), 472-6, 2008
